University of Queensland researchers have developed a drug that activates a hard-to-target immune receptor — a breakthrough that researchers say could lead to new treatments for neurodegenerative conditions like Motor Neurone Disease (MND). In an international collaboration with the Indian Institute of Technology, The University of Tokyo and… Read More
The University of Sheffield has been named as one of the winners of the Longitude Prize on ALS for a project using AI to combat motor neurone disease (MND). The global prize recognised the Sheffield-led ‘Decode ALS’ consortium as one of the world’s most promising multidisciplinary teams… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More
A global initiative has launched to close the gap in ALS/MND drug discovery. The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience announced the launch of ‘Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modelling’ (PRISM ALS), a collaborative effort to expand access to high-quality, patient-derived stem… Read More
The first participants have been dosed in the first-in-human Phase I clinical trial of NRG Therapeutics’ lead candidate NRG5051, which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s. NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, groundbreaking research showed the Covid-19 mRNA vaccine could boost cancer response. Elsewhere,… Read More
News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW. This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective… Read More
A successful treatment for amyotrophic lateral sclerosis (ALS) could be worth billions, a new report suggests. New research commission by Challenge Works and undertaken by the Office of Health Economics (OHE) estimates that a successful treatment for ALS, the most common form of motor neurone disease (MND),… Read More
PLL Therapeutics will present its strategic approach in the early detection and treatment of Amyotrophic Lateral Sclerosis (ALS), a form of motor neuron disease (MND), at the 19th Bioshares Biotech Summit. Bioshares is an Australian biotech stock report. The summit, hosting emerging life science companies listed on the ASX, with… Read More
Biogen’s Qalsody (tofersen) has been approved in the UK as the first therapy to treat a rare, genetic form of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND). The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for tofersen through the International… Read More
The Longitude Prize on ALS is a new £7.5 million ($10.28 million) global challenge prize to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND). Open for entries from 25 June… Read More
NRG Therapeutics has been awarded a non-dilutive grant from Target ALS Foundation to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease. It is one of five recipients of the 2024 In Vivo Target Validation grants… Read More
UK charity LifeArc has pledged £1.5 million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). The new partnership, which will involve scientists from both organisations working closely… Read More
A new project by researchers in Edinburgh aims to identify combinations of existing drugs that could be used together to treat motor neuron disease (MND). Led by Prof Siddharthan Chandran, the £3.3 million project is funded by the medical research charity LifeArc, as part of an… Read More
Medical research charity LifeArc and the MND Association have established a £1 million joint translational research fund to support researchers developing treatments for Motor Neurone Disease (MND). Despite recent advances, there is still no effective clinical treatment for MND. Each organisation is contributing £500,000 to the fund. Researchers from across… Read More
